|
US2021087552A1
|
|
Methods, Compositions, and Systems for Classification of Genetic Variants of Unknown Significance
|
|
US2021071225A1
|
|
Methods and Systems for the Rapid Detection of Microorganisms Using Recombinant Infectious Agents to Express an Indicator Subunit
|
|
US2021062239A1
|
|
Devices and Methods for Detecting Microorganisms Using Recombinant Reproduction-Deficient Indicator Bacteriophage
|
|
US2020399614A1
|
|
Methods for Producing Mutant Bacteriophages for the Detection of Listeria
|
|
WO2020252292A1
|
|
Ion-pairing free lc-ms bioanalysis of oligonucleotides
|
|
WO2020214811A1
|
|
Methods and systems for the detection of 11-oxo androgens by lc-ms/ms
|
|
US2020333331A1
|
|
Methods and Systems for Detecting Antibodies by Surface Plasmon Resonance
|
|
US2020326355A1
|
|
Methods and Systems to Measure Cannabidiol (CBD)
|
|
WO2020210206A1
|
|
Database reduction based on geographically clustered data to provide record selection for clinical trials
|
|
WO2020160190A1
|
|
Methods and systems for the rapid detection of listeria using infectious agents
|
|
WO2020123542A1
|
|
Self-contained apparatus and system for detecting microorganisms
|
|
US2020134571A1
|
|
Express tracking for patient flow management in a distributed environment
|
|
CA3110921A1
|
|
Methods and systems for measuring ascorbic acid
|
|
CA3101500A1
|
|
Methods and systems for lc-ms/ms proteomic genotyping
|
|
US2019355445A1
|
|
Methods and Systems for Identifying Subjects for Enrollment in Clinical Trials
|
|
WO2019217899A2
|
|
Compositions and methods to detect kidney fibrosis
|
|
WO2019210052A1
|
|
Methods and systems for determining the risk of developing ovarian cancer
|
|
AU2019261608A1
|
|
Indicator bacteriophage for selecting and monitoring for efficacy of therapeutics and methods for using same
|
|
CN111971305A
|
|
Sandwich enzyme-linked immunosorbent assay for identifying subjects who may benefit from treatment with a therapeutic agent
|
|
US2019279777A1
|
|
Data Management for Genetic Laboratory Testing
|
